$215.01
0.35% yesterday
NYSE, Feb 04, 10:10 pm CET
ISIN
US2358511028
Symbol
DHR

Danaher Stock price

$215.01
-23.19 9.74% 1M
-54.31 20.17% 6M
-14.54 6.33% YTD
-30.81 12.53% 1Y
-39.94 15.67% 3Y
+70.74 49.03% 5Y
+158.35 279.47% 10Y
NYSE, Closing price Tue, Feb 04 2025
+0.75 0.35%
ISIN
US2358511028
Symbol
DHR
Sector

Key metrics

Market capitalization $155.30b
Enterprise Value $169.23b
P/E (TTM) P/E ratio 40.67
EV/FCF (TTM) EV/FCF 31.95
EV/Sales (TTM) EV/Sales 7.09
P/S ratio (TTM) P/S ratio 6.50
P/B ratio (TTM) P/B ratio 3.12
Dividend yield 0.50%
Last dividend (FY24) $1.08
Revenue growth (TTM) Revenue growth -13.50%
Revenue (TTM) Revenue $23.88b
EBIT (operating result TTM) EBIT $4.86b
Free Cash Flow (TTM) Free Cash Flow $5.30b
Cash position $2.08b
EPS (TTM) EPS $5.29
P/E forward 36.88
P/S forward 6.44
EV/Sales forward 7.01
Short interest 0.95%
Show more

Is Danaher a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,821 stocks worldwide.

Danaher Stock Analysis

Unlock Scores for Free

Analyst Opinions

28 Analysts have issued a Danaher forecast:

22x Buy
79%
6x Hold
21%

Analyst Opinions

28 Analysts have issued a Danaher forecast:

Buy
79%
Hold
21%

Financial data from Danaher

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
23,875 23,875
14% 14%
100%
- Direct Costs 9,669 9,669
15% 15%
40%
15,963 15,963
1% 1%
67%
- Selling and Administrative Expenses 7,759 7,759
24% 24%
32%
- Research and Development Expense 1,584 1,584
5% 5%
7%
7,215 7,215
12% 12%
30%
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT 4,863 4,863
20% 20%
20%
Net Profit 3,899 3,899
18% 18%
16%

In millions USD.

Don't miss a Thing! We will send you all news about Danaher directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Danaher Stock News

Positive
Kiplinger
5 days ago
Meta Platforms fell of the Street's list of top-rated stocks this month but some surprising names made the cut.
Neutral
Seeking Alpha
7 days ago
Danaher Corporation (DHR) Q4 2024 Earnings Call Transcript
Negative
Reuters
7 days ago
Danaher on Wednesday missed Wall Street estimates for fourth-quarter profit due to soft demand for tools and services used in drug development by its biotech and pharmaceutical clients.
More Danaher News

Company Profile

Danaher Corp. operates as a medical company, which designs, manufactures, and markets professional, medical, industrial and commercial products and services. It operates through the following segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. The Life Sciences segment offers a range of research tools that scientists use to study the basic building blocks of life, including genes, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies and test new drugs and vaccines. The Diagnostics segment comprises of analytical instruments, reagents, consumables, software, and services that hospitals, physician's offices, reference laboratories, and other critical care settings use to diagnose disease and make treatment decisions. The Environmental & Applied Solution segment offers products and services that help protect important resources and keep global food and water supplies safe. The company was founded by Steven M. Rales and Mitchell P. Rales in 1969 and is headquartered in Washington, DC.

Head office United States
CEO Rainer Blair
Founded 1984
Website www.danaher.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today